List of Excipients in Branded Drug METFORMIN HCL ER

« Back to Dashboard

Generic Drugs Containing METFORMIN HCL ER

Company	Ingredient	NDC	Excipient
Northwind Pharmaceuticals	metformin hydrochloride extended release	51655-551	HYPROMELLOSES
Northwind Pharmaceuticals	metformin hydrochloride extended release	51655-551	MAGNESIUM STEARATE
Northwind Pharmaceuticals	metformin hydrochloride extended release	51655-551	POVIDONE
Northwind Pharmaceuticals	metformin hydrochloride extended release	51655-551	SILICON DIOXIDE
Northwind Pharmaceuticals	metformin hydrochloride extended release	51655-551	SODIUM CARBONATE
Northwind Pharmaceuticals	metformin hydrochloride extended release	51655-551	TALC
Northwind Pharmaceuticals	metformin hydrochloride extended release	51655-551	XANTHAN GUM

What are the Most Frequently-Used Excipients in METFORMIN HCL ER?

# Of NDCs	Excipient
1	HYPROMELLOSES
1	MAGNESIUM STEARATE
1	POVIDONE
1	SILICON DIOXIDE
1	SODIUM CARBONATE
1	TALC
1	XANTHAN GUM

Metformin HCl ER Excipient Strategy and Commercial Opportunities

Last updated: October 14, 2026

Metformin hydrochloride extended-release is a mature, high-volume generic product with limited active-ingredient differentiation. Commercial value is concentrated in excipient selection, release control, tablet size, gastrointestinal tolerability, manufacturing yield, and differentiated delivery formats.

The strongest opportunities are robust hydrophilic matrix systems, smaller high-load tablets, low-cost formulations with reliable fed and fasted bioequivalence, and differentiated products for adherence-sensitive patients. Novel excipients have limited commercial appeal because established excipients can meet most performance requirements without adding regulatory risk.

Key conclusions

• Metformin HCl ER is primarily an excipient-engineering and manufacturing opportunity, not an API exclusivity opportunity.
• Hydrophilic polymer matrices based on hypromellose remain the most practical platform.
• The main technical challenge is controlling release from a very high-dose, highly water-soluble drug.
• Commercial differentiation can come from tablet size, once-daily performance, reduced gastrointestinal effects, scoring, sprinkle capability, and manufacturing efficiency.
• The US generic market is mature and price competitive. Formulation patents, device-free delivery improvements, and international regulatory execution are more relevant than basic composition-of-matter protection.
• The principal regulatory risks are failure to match the reference product’s in vitro and in vivo release profile, food effects, alcohol-related dose dumping, and inadequate control of tablet mechanical properties.

What is the formulation challenge for metformin HCl extended release?

Metformin HCl is a high-dose, highly water-soluble drug that must be released gradually over an extended period. The formulation must prevent rapid dissolution while maintaining consistent exposure across fed and fasted conditions.

A typical commercial strength is 500 mg, 750 mg, or 1,000 mg of metformin HCl. The high drug load leaves limited room for excipients. Excipients must perform several functions within a compact tablet:

• Form a reproducible release-controlling barrier.
• Maintain tablet integrity during compression, coating, packaging, and gastrointestinal transit.
• Limit burst release after hydration.
• Avoid excessive tablet size.
• Support high-speed manufacturing.
• Produce acceptable dissolution across pH conditions.
• Limit food-related changes in release.
• Avoid alcohol-induced dose dumping.

The original Glucophage XR product uses a prolonged-release tablet design based on a polymeric matrix. Generic products use different matrix and manufacturing approaches, but each must satisfy FDA bioequivalence and quality requirements applicable to extended-release metformin products.[1,2]

Which excipients are most suitable for metformin HCl ER?

The highest-value excipient categories are hydrophilic matrix polymers, compression aids, binders, lubricants, glidants, coating systems, and release-modifying polymers.

Hydrophilic matrix polymers

Hypromellose, also called hydroxypropyl methylcellulose or HPMC, is the primary platform for a conventional extended-release matrix.

HPMC controls release by hydrating at the tablet surface, forming a gel layer, and regulating diffusion and erosion. Different viscosity grades materially affect performance. Low-viscosity grades can produce faster release and easier processing. High-viscosity grades form stronger gels and generally slow release more effectively.

The commercial advantages of HPMC include:

• Broad regulatory acceptance.
• Large global supply base.
• Established compendial specifications.
• Compatibility with direct compression and granulation.
• Availability in multiple viscosity and particle-size grades.
• Strong precedent in oral extended-release products.

Other matrix polymers may include:

• Hydroxypropyl cellulose.
• Polyethylene oxide.
• Carbomers.
• Sodium alginate.
• Xanthan gum.
• Ethylcellulose, usually in combination with other release-control systems.

Polyethylene oxide can produce strong gel matrices but may introduce higher sensitivity to processing conditions and polymer grade. Ethylcellulose is more useful in coating or multiparticulate systems than as the sole release-controlling excipient for a high-dose metformin tablet.

Fillers and compression aids

Microcrystalline cellulose is widely used to improve tabletability and structural integrity. Its concentration must be managed because metformin HCl already occupies much of the tablet mass.

Other options include:

• Mannitol for improved mouthfeel or lower hygroscopicity.
• Lactose where compatibility and process performance are acceptable.
• Dibasic calcium phosphate for density and compactability.
• Coprocessed excipients for direct compression.

A high-density filler can reduce tablet volume, but mineral fillers may alter dissolution, increase tablet hardness, or complicate content uniformity and granulation behavior. The optimal filler depends on the selected matrix system and compression process.

Binders

Povidone and low-substituted hydroxypropyl cellulose may support granulation and tablet strength. Hydroxypropyl cellulose can also contribute to matrix formation.

Excessive binder levels can delay disintegration of non-matrix regions, increase tablet hardness, and make dissolution less responsive to the intended polymer design. The formulation should use the minimum binder level that provides acceptable mechanical properties.

Lubricants and glidants

Magnesium stearate is commonly used, but over-lubrication can weaken interparticle bonding and slow wetting. Talc, colloidal silicon dioxide, and sodium stearyl fumarate may be considered depending on the process.

Lubricant sensitivity is important for metformin ER because a formulation can show acceptable assay and hardness while displaying an altered release profile after changes in blending time or lubricant concentration.

Film-coating systems

A film coat can improve swallowability, appearance, moisture protection, and product identification. Typical systems may include hypromellose, polyethylene glycol, titanium dioxide where permitted, and colorants.

The film coat should not be treated as the main release-control mechanism unless the product uses a reservoir, multiparticulate, or coated-core design. For a conventional matrix tablet, the core formulation normally determines the principal release profile.

What formulation architectures protect metformin HCl ER products?

Three formulation architectures have the greatest commercial relevance.

Architecture	Main excipient strategy	Commercial strengths	Main risks
Hydrophilic matrix tablet	HPMC or related gel-forming polymer	Low cost, scalable, established regulatory path	Dose dumping, food effect, tablet size
Coated matrix or reservoir system	Ethylcellulose, HPMC, pore formers, polymer coatings	Greater release-control flexibility	More process steps and higher cost
Multiparticulate or sprinkle system	Coated beads, pellets, or granules	Potential swallowing and administration advantages	More complex manufacturing and bioequivalence work

The hydrophilic matrix is usually the preferred first product because it has the lowest manufacturing and regulatory complexity. Multiparticulates may offer stronger differentiation but require tighter control of particle-size distribution, coating weight gain, capsule or sachet filling, dose uniformity, and release performance.

A sprinkle product could target patients who have difficulty swallowing conventional tablets. Its commercial value depends on demonstrating that administration with soft food does not alter bioavailability or release characteristics.

How should an excipient platform be designed for commercial manufacturing?

The formulation should be developed around critical material attributes and critical process parameters rather than a fixed excipient list.

Critical material attributes

Important attributes include:

• HPMC viscosity grade.
• Polymer particle size.
• Polymer moisture content.
• Metformin HCl particle-size distribution.
• Bulk and tapped density.
• Filler compressibility.
• Lubricant specific surface area.
• Excipient water activity.
• Granule porosity.
• Coating polymer molecular weight and solids content.

Critical process parameters

Key parameters include:

• Blend time.
• Granulation endpoint.
• Granulation liquid addition rate.
• Drying temperature and endpoint.
• Milling screen size.
• Lubrication time.
• Compression force.
• Tablet dwell time.
• Coating weight gain.
• Coating inlet and outlet temperatures.

A commercial formulation should tolerate normal variation in these parameters. A release profile that depends on a narrow compression-force window or exact polymer moisture level creates avoidable manufacturing risk.

The most attractive formulation is not necessarily the one with the fastest dissolution development cycle. It is the one that maintains release, hardness, friability, assay, and content uniformity across scale-up and routine production.

What FDA regulatory requirements apply to metformin HCl ER?

Metformin HCl ER products are generally developed through the abbreviated new drug application pathway in the United States. The reference product is Glucophage XR, marketed by Bristol-Myers Squibb and later subject to generic competition.

Extended-release products require more than conventional immediate-release dissolution matching. Sponsors must address:

• Comparative dissolution across multiple media.
• Fed and fasted bioequivalence.
• Strength proportionality where applicable.
• Alcohol interaction and dose-dumping risk.
• Multiple-dose or single-dose requirements specified by the FDA product-specific guidance.
• Stability under the proposed packaging system.
• Manufacturing consistency across commercial-scale batches.

The FDA’s product-specific guidance for metformin hydrochloride extended-release tablets provides the principal development framework for ANDA sponsors.[2] The final testing package depends on the proposed strength, formulation, dosage form, and reference product relationship.

The formulation should be evaluated under alcohol concentrations relevant to the FDA’s expectations because certain polymer matrices can lose integrity or release drug too rapidly in the presence of ethanol. The FDA has treated alcohol-induced dose dumping as a material safety and product-quality issue for modified-release oral products.[3]

When does metformin HCl ER lose exclusivity?

Metformin HCl has no meaningful remaining composition-of-matter exclusivity in the United States. The original extended-release product also faces a mature generic market.

The commercial protection for metformin ER has historically depended on:

• Drug substance patents that are expired.
• Extended-release formulation patents that have expired or provide limited practical protection.
• Manufacturing-process patents.
• Method-of-use patents, where listed or enforceable.
• Regulatory exclusivity associated with a specific approval, if applicable.
• Product-specific execution advantages that are not necessarily patent protected.

The FDA Orange Book is the controlling source for current listed patents and exclusivity status.[4] For a generic sponsor, the key legal exercise is a current Orange Book review combined with prosecution-history analysis, claim construction, and freedom-to-operate work. A general excipient composition is unlikely to create durable exclusivity unless the claims require a specific polymer system, release profile, process, or administration method.

What patent opportunities exist for metformin ER excipients and formulations?

The strongest patent opportunities are narrow and performance-based.

Formulation patents

Potential claim areas include:

• Defined HPMC viscosity ranges.
• Specific polymer-to-drug ratios.
• Multi-polymer matrix systems.
• Controlled tablet porosity.
• Low-dose or high-dose matrix configurations.
• Tablet hardness and dissolution relationships.
• Coated-core or multilayer tablets.
• Multiparticulate bead or pellet systems.
• Sprinkle formulations.
• Reduced-size tablets with equivalent exposure.
• Formulations that reduce gastrointestinal adverse effects.
• Alcohol-resistant release systems.

A claim that merely recites metformin HCl, HPMC, a filler, lubricant, and a coating may face substantial validity and obviousness pressure because similar oral matrix technologies are well established.

Method-of-use patents

Commercially relevant method claims could address:

• Once-daily administration.
• Administration with a specific meal pattern.
• Use in patients with gastrointestinal intolerance.
• Swallowing-impaired populations.
• Combination treatment with other antidiabetic agents.

Method-of-use claims must be evaluated separately from formulation claims. They may create narrower market protection and may not prevent all generic substitution.

Manufacturing patents

Manufacturing claims may cover:

• High-shear granulation conditions.
• Controlled polymer distribution.
• Compression methods that create a target porosity.
• Coating processes that improve alcohol resistance.
• Continuous manufacturing.
• Low-moisture processing for improved stability.
• In-line process controls for release-critical attributes.

Manufacturing patents can create licensing opportunities even where the final tablet composition is conventional.

Which commercial opportunities are strongest for metformin HCl ER?

The opportunity is strongest where an excipient change solves a specific commercial problem.

Opportunity	Patient or buyer value	Technical route	Commercial attractiveness
Smaller 1,000 mg tablet	Easier swallowing and lower packaging volume	Higher drug loading, optimized granulation, stronger matrix	High
Improved GI tolerability	Better persistence and adherence	Slower initial release, lower peak exposure, food-effect control	High
Sprinkle or capsule format	Use by patients with swallowing difficulty	Multiparticulates or coated granules	Medium to high
Lower-cost direct compression	Higher manufacturing margin	Robust coprocessed excipient and optimized tooling	High
Alcohol-resistant release	Regulatory and safety differentiation	Stronger polymer gel or coated system	Medium
Dual-layer tablet	Separate loading and maintenance phases	Layered compression and independent release zones	Medium
Pediatric or geriatric format	Administration flexibility	Granules, sachets, or low-swallow-burden dosage form	Medium
Fixed-dose combination platform	Reduced pill burden	Compatibility-validated bilayer or matrix design	High, but technically complex

A smaller tablet is commercially attractive because metformin doses are large and swallowing difficulty is a common product complaint. The formulation must preserve total exposure and release duration while reducing tablet volume. Higher drug loading alone may compromise tablet strength, friability, or release control.

Improved tolerability is more difficult to protect but potentially valuable. The product must show a meaningful clinical or patient-use benefit, not only a modified dissolution curve. A formulation that reduces early exposure without creating subtherapeutic trough concentrations has a stronger commercial rationale.

How does metformin HCl ER compare with immediate-release metformin?

Attribute	Immediate-release metformin	Extended-release metformin
Dosing frequency	Often multiple daily doses	Commonly once daily or less frequent
Release control	Rapid dissolution and absorption	Polymer or coating-controlled release
Tablet burden	Higher across the day	Lower dosing frequency
GI tolerability	May be more problematic for some patients	May improve tolerability for some users
Formulation complexity	Lower	Higher
Bioequivalence burden	Conventional	Fed, fasted, dissolution, and dose-dumping evaluation
Excipient value	Primarily manufacturability	Release control, size, robustness, and tolerability
Generic competition	Very mature	Mature, with greater formulation complexity

The commercial advantage of ER is adherence and tolerability, not a fundamentally different pharmacology. This limits premium pricing but supports product selection in formularies and patient segments where once-daily dosing matters.

What generic launch risks exist for metformin HCl ER?

The major generic launch risks are technical rather than patent-driven.

Dissolution mismatch

A formulation may match the reference product at one pH and diverge at another. Metformin ER development should examine release across acidic and neutral media and use discriminatory methods that can detect polymer or process changes.

Food effect

Food can change gastric residence time, hydration, and tablet erosion. A product that performs well in the fasted state may show excessive exposure or prolonged release after a meal.

Dose dumping

Alcohol, damaged film coating, insufficient polymer gel strength, or excessive tablet porosity can create rapid release. This issue can affect both regulatory approval and post-approval manufacturing changes.

Scale-up failure

Changes in granulation energy, drying endpoint, milling, lubricant blending, or compression can alter the release profile without changing assay or appearance.

Tablet size

Reducing tablet size may improve adherence but can narrow the process window. High drug loading can create weak tablets, capping, sticking, or variable dissolution.

Supply-chain concentration

HPMC and other specialty polymers are available from multiple suppliers, but switching grades or suppliers can change viscosity, particle size, hydration, and release. Supplier qualification must be treated as a release-critical activity.

What is the competitive landscape for metformin HCl ER?

The market includes branded and generic metformin ER tablets, multiple manufacturers, contract development and manufacturing organizations, and excipient suppliers.

The competitive basis is generally:

• Lowest sustainable cost of goods.
• Reliable ANDA approval.
• Stable commercial-scale release performance.
• Manufacturing capacity and supply continuity.
• Formulation flexibility across 500 mg, 750 mg, and 1,000 mg strengths.
• Hospital, retail, and mail-order contracting.
• Ability to support international registrations.
• Product differentiation in tablet size or administration method.

Revenue exposure is meaningful because metformin is one of the most widely prescribed diabetes medicines, but unit prices are low and generic substitution is extensive. A formulation supplier is more likely to capture value through platform adoption across several products than through a single metformin franchise.

The best licensing targets are technologies that transfer to other high-dose, highly soluble drugs requiring extended release. A polymer matrix, coating process, continuous manufacturing method, or compact-tablet platform with metformin data can be reused in other cardiovascular, metabolic, and neurologic products.

What geographic markets offer the strongest excipient opportunities?

The United States offers the clearest regulatory framework but has intense generic price pressure. Europe rewards reliable supply, manufacturing efficiency, and country-specific registration execution. Emerging markets may offer stronger volume growth but more variable reimbursement, local manufacturing requirements, and pricing controls.

A global excipient strategy should prioritize:

• Compendial excipients with established regional acceptance.
• Dual sourcing for HPMC and critical lubricants.
• Documentation supporting ICH quality systems.
• Excipient change-control packages.
• Local regulatory expectations for colorants, coatings, and novel excipients.
• Packaging systems that control moisture during distribution.

For international markets, a conventional HPMC matrix is generally more portable than a novel excipient system requiring jurisdiction-specific safety documentation.

How strong is the patent estate for metformin HCl ER?

The core patent estate is weak for blocking purposes because metformin and conventional extended-release technologies are mature. Patent strength is higher for narrowly defined systems with demonstrated performance advantages.

Patent category	Expected strength	Commercial relevance
Metformin composition of matter	Low or expired	Minimal
Basic HPMC matrix	Low to moderate	Limited blocking value
Specific polymer ratio and dissolution profile	Moderate	Relevant if technically distinctive
Multiparticulate or sprinkle format	Moderate	Potentially valuable
Alcohol-resistant system	Moderate	Regulatory and safety relevance
Reduced-size high-load tablet	Moderate	Strong commercial positioning
Manufacturing process	Moderate to high if narrow and difficult to design around	Licensing and supply-chain value
Method of use	Variable and narrow	Segment-specific

A strong patent position requires more than a list of familiar excipients. The claims should connect composition or process variables to a measurable release, exposure, tolerability, or manufacturing outcome.

Key Takeaways

• Metformin HCl ER is a mature generic market with limited API-based exclusivity.
• HPMC hydrophilic matrices remain the most practical excipient platform.
• The highest-value formulation objectives are smaller tablets, stable once-daily release, lower food sensitivity, and improved gastrointestinal tolerability.
• Generic sponsors must manage dissolution, food effect, alcohol dose dumping, scale-up, and supplier variability.
• Conventional excipient combinations have limited patent strength unless linked to specific performance parameters.
• Multiparticulate, sprinkle, multilayer, and high-drug-load compact-tablet technologies offer the clearest differentiation.
• Manufacturing-process patents and transferable excipient platforms may produce more durable commercial value than a basic composition patent.
• The US market is attractive for volume and regulatory clarity but exposed to intense price competition.
• Excipient suppliers should position metformin ER data as part of a broader high-dose modified-release platform.

FAQs About Metformin HCl ER Excipients and Commercial Strategy

Which HPMC grade is best for metformin HCl ER?

No single grade is universally optimal. The appropriate HPMC viscosity and particle-size grade depend on drug loading, tablet geometry, compression force, target dissolution profile, and manufacturing process. High-viscosity grades generally provide stronger release control, but they can increase processing difficulty and tablet size.

Can metformin ER be made by direct compression?

Yes. Direct compression can reduce manufacturing cost and process complexity, but the excipient system must provide adequate flow, compactability, content uniformity, and release control. High drug loading and poor powder flow can make direct compression less robust than dry or wet granulation.

What excipient reduces metformin gastrointestinal side effects?

No excipient guarantees reduced gastrointestinal effects. A controlled-release polymer system can reduce the rate of drug release and may improve tolerability for some patients, but the benefit must be supported by comparative clinical or pharmacokinetic data.

Are novel excipients commercially attractive for metformin ER?

Usually not for a first generic product. Established polymers such as HPMC offer lower regulatory risk, broad supply availability, and extensive precedent. Novel excipients become more attractive only when they provide a measurable advantage in tablet size, release robustness, administration flexibility, or tolerability.

Can a metformin ER formulation be patented without a new excipient?

Yes. Patentable subject matter may include a specific ratio of known excipients, a defined dissolution profile, a manufacturing process, a multiparticulate structure, a reduced-size high-load tablet, or a demonstrated pharmacokinetic or tolerability advantage. The claims must be technically specific and sufficiently distinct from prior art.

References

1. U.S. Food and Drug Administration. (n.d.). Glucophage XR (metformin hydrochloride) extended-release tablets prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Product-specific guidance for metformin hydrochloride extended-release tablets.
3. U.S. Food and Drug Administration. (2015). FDA’s approval of new labeling for certain extended-release and long-acting opioid analgesics and alcohol-induced dose dumping considerations.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
5. U.S. Pharmacopeial Convention. (n.d.). United States Pharmacopeia and National Formulary: Metformin hydrochloride and related excipient monographs.
6. DailyMed. (n.d.). Metformin hydrochloride extended-release tablet labels. National Library of Medicine.